Ionela Nicoleta Irimescu

Mrs. Ionela Nicoleta Irimescu

Medical Physicist in Laboratory of Nuclear Medicine, Institute of Oncology ”Prof. Dr. Alexandru Trestioreanu” Bucharest
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MGMirela Gherghe
Mirela Gherghe
MMMario-Demian Mutuleanu
Mario-Demian Mutuleanu
ASAdina Elena Stanciu
Adina Elena Stanciu
IIIonela Nicoleta Irimescu
Ionela Nicoleta Irimescu
ALAlexandra Maria Lazar
Alexandra Maria Lazar
RARodica Maricela Anghel
Rodica Maricela Anghel
Purpose: To assess the potential added value of the SPECT-CT quantitative analysis in metastatic breast cancer lesions detection and differentiation from degenerative lesions. Methods: This prospective monocentric study was conducted on 70 female patients who underwent SPECT-CT bone scans using 99mTc–HDP that identified the presence of metastatic bone lesions and degenerative lesions in each patient. Once the lesions were identified, a quantitative analysis of radiotracer uptake was conducted. The highest one to five SUVmax values for both metastatic and degenerative bone lesions were identified in each patient and the data were then statistically analyzed. Results: The SUVmax value was significantly higher in metastatic bone lesions than in degenerative lesions (p < 0.001). The diagnostic accuracy of SPECT-CT quantitative data analysis revealed a sensitivity of 91.5% and a specificity of 93.3% at a cut-off value of the SUVmax of 16.6 g/mL. Conclusion: Quantitative analysis performed using SPECT-CT data can improve the diagnostic accuracy in differentiating between metastatic bone lesions and degenerative lesions, thus leading to appropriate treatment and better follow-up in metastatic breast cancer patients.

23 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MGMirela Gherghe
Mirela Gherghe
MMMario-Demian Mutuleanu
Mario-Demian Mutuleanu
ASAdina Elena Stanciu
Adina Elena Stanciu
IIIonela Nicoleta Irimescu
Ionela Nicoleta Irimescu
ALAlexandra Maria Lazar
Alexandra Maria Lazar
RARodica Maricela Anghel
Rodica Maricela Anghel
Background: Cancer represents the major cause of death mainly through its ability to spread to other organs, highlighting the importance of metastatic disease diagnosis and accurate follow up for treatment management purposes. Although until recently the main method for imaging interpretation was represented by qualitative methods, quantitative analysis of SPECT-CT data represents a viable, objective option. Methods: Seventy-five breast cancer patients presenting metastatic bone disease underwent at least two Bone SPECT-CT studies using [99mTc]-HDP between November 2019 to October 2022. Results: Our findings show a good positive relationship between the qualitative methods of imaging interpretation and quantitative analysis, with a correlation coefficient of 0.608 between qualitative whole body scintigraphy and quantitative SPECT-CT, and a correlation coefficient of 0.711 between the qualitative and quantitative interpretation of SPECT-CT data; nevertheless, there is a need for accurate, objective and reproducible methods for imaging interpretation, especially for research purposes. Conclusions: Quantitative evaluation of the SPECT-CT data has the potential to be the first choice of imaging interpretation for patient follow up and treatment response evaluation, especially for research purposes, because of its objectivity and expression of uptake changes in absolute units.

15 January 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MGMirela Gherghe
Mirela Gherghe
ALAlexandra Maria Lazar
Alexandra Maria Lazar
Laurentiu SimionLaurentiu Simion
Laurentiu Simion
IIIonela Nicoleta Irimescu
Ionela Nicoleta Irimescu
MSMaria-Carla Sterea
Maria-Carla Sterea
RARodica Maricela Anghel
Rodica Maricela Anghel
(1) Background: The aim of our study was to assess the feasibility of 99mTcEDDA/HYNIC-TOC SPECT/CT quantitative analysis in evaluating treatment response and disease progression in patients with NETs. (2) Methods: This prospective monocentric study evaluated 35 SPECT/CT examinations performed on 14 patients with neuroendocrine tumours who underwent a baseline and at least one follow-up 99mTcEDDA/HYNIC-TOC scan as part of their clinical management. The examination protocol included a whole-body scan acquired 2 h after the radiotracer’s administration, with the SPECT/CT performed 4 h post-injection. Images were analyzed by two experienced physicians and patients were classified into response categories based on their changes in SUV values. (3) Results: We evaluated 14 baseline studies and 21 follow-up scans, accounting for 123 lesions. A statistically positive correlation has been found between the SUVmax and SUVpeak values in tumoral lesions (p < 0.05). No correlation has been found between the SUV values and the ki67 proliferation index. Finally, 64.29% patients were classified as SD at the end of the study, with only 14.29% of patients exhibiting PD and 21.43% patients with PR. (4) Conclusions: The quantitative analysis of 99mTcEDDA/HYNIC-TOC SPECT/CT data in patients with neuroendocrine tumours could represent an alternative to 68Ga-DOTA-peptides PET/CT for the monitoring and prognosis of NETs.